22 SEPTEMBER 2009
NORTHERN 3 VCT PLC
PORTFOLIO UPDATE
Northern 3 VCT PLC ("the Company") announces the sale of its
investment in DxS Limited, which provides molecular diagnostic
products and services to the healthcare industry, for initial cash
proceeds of £3.3 million, plus £0.3 million by way of accrued loan
stock interest. The Company may become entitled to receive up to a
further £2.5 million over the period to 2012 subject to the
achievement by DxS of specified objectives.
The initial sale price represents an uplift of £0.6 million
(equivalent to 2.2p per ordinary share in the Company) over the
carrying value of the investment as reflected in the unaudited net
asset value of 86.4p per share as at 30 June 2009 which was announced
by the Company on 30 July 2009.
The Company invested a total of £0.3 million in DxS in early-stage
funding rounds led by NVM Private Equity in 2004 and 2006. The total
income and capital proceeds to date (excluding contingent future
payments) represent a money multiple of 11.1 times the original
investment and an internal rate of return (IRR) of 60.4% per annum.
Enquiries:
Tim Levett/Christopher Mellor, NVM Private Equity Limited - 0191 244
6000
---END OF MESSAGE---
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.